GGrantIndex
← Leaderboards

Benjamin Levi

University Of Michigan At Ann Arbor

$10,166,720
Attributed
$13,086,538
Total exposure
10
Grants
9
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.4M · FY200925
$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$13,086,538 · 10

By mechanism

R01$10,593,869 · 5
R61$786,192 · 1
K08$784,640 · 1
R33$410,000 · 1
R21$400,693 · 1
F32$111,144 · 1

Top collaborators

Most similar at University Of Michigan At Ann Arbor

Same institution · by research overlap

Others in their field

Top investigators on “In Vivo

Research focus

In VivoPreventSignal TransductionHeterotopic OssificationSiteBoneCellsPathway InteractionsBurn InjuryInjuryOsteogenesisPathologicOperative Surgical ProceduresMouse ModelJointsMusculoskeletal InjuryMediatingTraumaMesenchymal Stem CellsExcisionInsightHip Replacement ArthroplastyGeneticPrevention

Grant awards (37)

Targeting jmjd3 mitigates heterotopic ossification$597,156
R01 · FY2025 · AR
Unraveling the role of PIEZO mediated mechanosensory signaling in pediatric clubfoot deformity repair$400,693
R21 · FY2025 · AR · contact PI
Impacts of mechanosensation and matrix architecture on cell fate specification in traumatic heterotopic ossification$398,253
R01 · FY2025 · AR · contact PI
Targeting jmjd3 mitigates heterotopic ossification$597,156
R01 · FY2024 · AR
Impact of peripheral nerves on mesenchymal cell fate in extremity trauma$576,704
R01 · FY2024 · AR · contact PI
Impacts of mechanosensation and matrix architecture on cell fate specification in traumatic heterotopic ossification$441,016
R01 · FY2024 · AR · contact PI
Impact of peripheral nerves on mesenchymal cell fate in extremity trauma$593,021
R01 · FY2023 · AR · contact PI
Impact of peripheral nerves on mesenchymal cell fate in extremity trauma$589,600
R01 · FY2023 · AR · contact PI
Impacts of mechanosensation and matrix architecture on cell fate specification in traumatic heterotopic ossification$433,381
R01 · FY2023 · AR · contact PI
Neutrophil Biomarker and neutrophil targeted therapy to predict and prevent heterotopic ossification$410,000
R33 · FY2023 · AR · contact PI
Impacts of mechanosensation and matrix architecture on cell fate specification in traumatic heterotopic ossification$139,195
R01 · FY2023 · AR · contact PI
Targeting jmjd3 mitigates heterotopic ossification$609,471
R01 · FY2022 · AR
Impact of peripheral nerves on mesenchymal cell fate in extremity trauma$602,910
R01 · FY2022 · AR · contact PI
Impacts of mechanosensation and matrix architecture on cell fate specification in traumatic heterotopic ossification$435,118
R01 · FY2022 · AR · contact PI
Impacts of mechanosensation and matrix architecture on cell fate specification in traumatic heterotopic ossification - diversity supplement$127,595
R01 · FY2022 · AR · contact PI
Targeting jmjd3 mitigates heterotopic ossification$643,472
R01 · FY2021 · AR
Impact of peripheral nerves on mesenchymal cell fate in extremity trauma$629,454
R01 · FY2021 · AR · contact PI
Impacts of mechanosensation and matrix architecture on cell fate specification in traumatic heterotopic ossification$428,360
R01 · FY2021 · AR · contact PI
Neutrophil Biomarker and neutrophil targeted therapy to predict and prevent heterotopic ossification$377,442
R61 · FY2021 · AR · contact PI
Targeting Molecular and Cellular Mediators of Inflammation to Prevent Pathologic Cell Differentiation and Heterotopic Ossific$287,769
R01 · FY2021 · AR · contact PI
Neutrophil Biomarker and neutrophil targeted therapy to predict and prevent heterotopic ossification$408,750
R61 · FY2020 · AR · contact PI
Developing New Diagnostic and Timed, TAK1 Specific Treatment Strategies for Trauma Induced Heterotopic Ossification$301,380
R01 · FY2020 · GM · contact PI
Targeting Molecular and Cellular Mediators of Inflammation to Prevent Pathologic Cell Differentiation and Heterotopic Ossific$240,267
R01 · FY2020 · AR · contact PI
Targeting Molecular and Cellular Mediators of Inflammation to Prevent Pathologic Cell Differentiation and Heterotopic Ossification$55,185
R01 · FY2020 · AR · contact PI
Targeting Molecular and Cellular Mediators of Inflammation to Prevent Pathologic Cell Differentiation and Heterotopic Ossification$306,900
R01 · FY2019 · AR · contact PI
Developing New Diagnostic and Timed, TAK1 Specific Treatment Strategies for Trauma Induced Heterotopic Ossification$296,400
R01 · FY2019 · GM · contact PI
Targeting Molecular and Cellular Mediators of Inflammation to Prevent Pathologic Cell Differentiation and Heterotopic Ossification$306,900
R01 · FY2018 · AR · contact PI
Developing New Diagnostic and Timed, TAK1 Specific Treatment Strategies for Trauma Induced Heterotopic Ossification$296,400
R01 · FY2018 · GM · contact PI
Developing New Diagnostic and Timed, TAK1 Specific Treatment Strategies for Trauma Induced Heterotopic Ossification$59,406
R01 · FY2018 · GM · contact PI
Targeting Molecular and Cellular Mediators of Inflammation to Prevent Pathologic Cell Differentiation and Heterotopic Ossification$306,900
R01 · FY2017 · AR · contact PI
Developing New Diagnostic and Timed, TAK1 Specific Treatment Strategies for Trauma Induced Heterotopic Ossification$294,500
R01 · FY2017 · GM · contact PI
Novel Pathway and Prevention Strategy for Heterotopic Ossification$196,160
K08 · FY2017 · GM · contact PI
Novel Pathway and Prevention Strategy for Heterotopic Ossification$196,160
K08 · FY2016 · GM · contact PI
Novel Pathway and Prevention Strategy for Heterotopic Ossification$196,160
K08 · FY2015 · GM · contact PI
Novel Pathway and Prevention Strategy for Heterotopic Ossification$196,160
K08 · FY2014 · GM · contact PI
Enhancement Of Bone Regeneration From Human Adipose-Derived Stromal Cells$56,790
F32 · FY2010 · AR · contact PI
Enhancement Of Bone Regeneration From Human Adipose-Derived Stromal Cells$54,354
F32 · FY2009 · AR · contact PI